Main
Multiple myeloma, plasma cell malignancy, MM
MULTIPLE MYELOMA, MYELOMA, REFRACTORY MULTIPLE MYELOMA
Multiple myeloma (MM) is an incurable plasma cell malignancy. Clinical outcomes remain poor for patients with relapsed or refractory multiple myeloma (RRMM) after therapy with at least one proteasome inhibitor, one immunomodulatory drug and one CD38-directed antibodyNovel BCMA-directed therapies include antibody–drug conjugates (ADCs), chimeric antigen receptor T cell (CAR-T) therapies and T-cell-engaging bispecific antibodies. In the United States, three BCMA-targeted therapies are currently approved to treat patients with RRMM. Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), both CAR-T-cell therapies, showed an objective response rate (ORR) of 67.1% (94/140) and 83.2% (94/113), respectively, in patients who underwent leukapheresisElranatamab (PF-06863135) is a humanized bispecific IgG2 antibody targeting BCMA on myeloma cells and CD3 on T cells. Elranatamab activates and directs T cells to induce a selective cytotoxic T cell response against myeloma cells